In a follow-up study, the authors preclinically examined the pharmacodynamics and toxicity of this CAAR and showed that the desmoglein 3-CAAR T cells specifically deplete primary human desmoglein 3-specific B cells from PV patients and is effective in an active animal model of PV (62). The gene discussed is DSG3; the disease is acquired polycythemia vera.